Lion's Mane for Cognitive Function

Verdict: Weak, inconsistent evidence; benefits unproven

Lion's Mane shows only a faint, inconsistent cognitive signal in a handful of small, mostly industry-funded trials, and no benefit has been established. Health authorities and major clinics agree the human evidence is too thin to recommend it for brain health.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade rests on just four small, low-quality randomized trials (n=18-41), nearly all single-site and mostly industry-funded, with no meta-analysis to anchor a stronger verdict. The most cited, Mori 2009 (PMID 18844328), found higher cognitive scores in adults with mild cognitive impairment at weeks 8-16, but the benefit faded within four weeks of stopping, so it was neither durable nor clearly generalizable to healthy people.

Results in healthy adults are mixed and underpowered. A 2023 pilot (PMID 38004235) saw faster acute Stroop reaction times but only a non-significant trend for stress (p=0.051), and a 2025 acute trial (PMID 40276537) found no effect on global cognition, with an isolated psychomotor improvement only. An earlier trial (PMID 31413233) improved MMSE alone while other measures stayed flat.

Regulators and clinicians reinforce the caution. The FDA ceased evaluating the GRAS notice and has sent warning letters to sellers making disease claims, while EFSA has not endorsed any claim. Mayo Clinic and Harvard Health call the human evidence insufficient or poor quality, Cleveland Clinic notes the nerve-growth-factor mechanism comes only from non-human studies, and the Alzheimer's Association says no supplement is proven to benefit cognition. Hence a weak, warning-flagged C.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.48
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
76%
Broadly consistent
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.40
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L11 AI re-checkIndependent read
0.50
L2 PubMedPrimary literature
0.60
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.48
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial
PMID: 18844328 2009 RCT (double-blind) n = 30
Finding: Treatment group scored significantly higher than placebo at weeks 8, 12, 16; benefit faded by week 20 (4 weeks after stopping).
🟠 Limited quality ⚠️ Industry-funded
View on PubMed
Improvement of cognitive functions by oral intake of Hericium erinaceus
PMID: 31413233 2019 RCT (double-blind)
Finding: MMSE alone showed significant improvement vs placebo; other measures not significant; p-values not stated.
🟠 Limited quality
View on PubMed
The Acute and Chronic Effects of Lion's Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Pilot Study
PMID: 38004235 2023 RCT (double-blind) n = 41
Finding: Acute: faster Stroop reaction times at 60min post-dose (p=0.005); Chronic: only a trending reduction in stress after 28 days (p=0.051).
🟠 Limited quality ⚠️ Industry-funded
View on PubMed
Acute effects of a standardised extract of Hericium erinaceus on cognition and mood in healthy younger adults: a double-blind randomised placebo-controlled study
PMID: 40276537 2025 RCT (double-blind) n = 18
Finding: No significant effect on global cognition or mood; isolated improvement on pegboard (psychomotor) test only.
🟠 Limited quality ⚠️ Industry-funded
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
At the notifier's request, FDA ceased to evaluate this notice source↗
L4d TW TFDA / 衛福部
Supportive
食品營養成份資料庫 - 猴頭菇 source↗
L5b Mayo Clinic
Cautious
It is unknown whether these mushrooms truly have positive effects on health conditions; the Natural Medicines database shows insufficient reliable evidence available to rate most claims of effectiveness. source↗
L5c Cleveland Clinic
Cautious
Non-human studies show that lion's mane mushrooms have compounds that stimulate the production of nerve growth factor (NGF), which helps grow brain cells and may enhance memory and focus. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-cognitive-function-INT-lions-mane-001 繁體中文版 →